Published online October 26, 2009
PEDIATRICS Vol. 124 No. 5 November 2009, pp. 1344-1347 (doi:10.1542/peds.2008-3750)
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Google Scholar
Right arrow Articles by Kishiyama, C. M.
Right arrow Articles by Chase, H. P.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kishiyama, C. M.
Right arrow Articles by Chase, H. P.
Related Collections
Right arrow Endocrinology
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

ARTICLE

A Pilot Trial of Pramlintide Home Usage in Adolescents With Type 1 Diabetes

Christopher M. Kishiyama, MD, Patricia L. Burdick, BS, Erin C. Cobry, BS, Victoria L. Gage, RN, Laurel H. Messer, RN, Kim McFann, PhD and H. Peter Chase, MD

Department of Pediatrics, University of Colorado, Aurora, Colorado

OBJECTIVE: The objective of this study was to evaluate the safety and efficacy of home pramlintide use in adolescents with type 1 diabetes.

PATIENTS AND METHODS: This was a randomized, 28-day pilot trial of pramlintide (maximum dose: 30 µg per meal) in 10 adolescents aged 13 to 17 years. End points included changes in hemoglobin A1c (HbA1c) values, body weight, and postprandial peak blood glucose levels and area under the curve on continuous glucose monitoring.

RESULTS: Changes in HbA1c values, body weight, and total insulin dose declined in the treatment group compared with the control group (bootstrapped, P ≤ .02 for each). The treatment group also demonstrated lower average dinner area under the curve (P = .02) and lower maximum breakfast (P = .03) and dinner (P = .02) postprandial blood glucose values.

CONCLUSIONS: Pramlintide can help some adolescents to decrease postprandial hyperglycemia, HbA1c values, body weight, and insulin dosages. Additional large-scale trials should now be considered.

Key Words: Pramlintide • adolescents • type1 diabetes

Abbreviations: HbA1c—hemoglobin A1c • CTRC—Clinical Translational Research Center • BG—blood glucose • AUC—area under the curve

Accepted Jun 5, 2009.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?